(Q42797006)

7 November 2017

title

Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models (English)

1 reference

https://api.crossref.org/works/10.2217/IMT.10.71

7 November 2017

Trastuzumab (Herceptin ® ): Overcoming Resistance in HER2 -Overexpressing Breast Cancer Models (English)

1 reference

30 August 2024

1 reference

1 reference

Huguette Albrecht

1

1 reference

7 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21091112

30 August 2024

publication date

1 November 2010

1 reference

full work available at URL

7 November 2017

https://www.tandfonline.com/doi/pdf/10.2217/imt.10.71

1 reference

https://api.crossref.org/works/10.2217/IMT.10.71

30 August 2024

1 reference

7 November 2017

volume

2

1 reference

7 November 2017

issue

6

1 reference

7 November 2017

page(s)

795-798

1 reference

Untangling the ErbB signalling network

7 November 2017

cites work

1 reference

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

Trastuzumab: triumphs and tribulations

21 January 2018

1 reference

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

21 January 2018

1 reference

Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer

21 January 2018

1 reference

Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

The tumor microenvironment and its role in promoting tumor growth

21 January 2018

1 reference

Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data

21 January 2018

1 reference

Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer

21 January 2018

1 reference

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217/IMT.10.71

21 January 2018

Development of herceptin

series ordinal

1

1 reference

30 August 2024

Identifiers

DOI

10.2217/IMT.10.71

1 reference

7 November 2017

1 reference